HRTX Heron Therapeutics, Inc.
Legal ·
The court ruled June 1, 2026 in Heron's patent suit against Azurity Pharmaceuticals and Slayback Pharma entities. Heron says it will appeal to the Federal Circuit and that the ruling does not affect a prior settlement.
Heron's board adopted a Tax Benefit Preservation Plan on August 13, 2025. A holder that reaches 4.99% without board approval would trigger rights, and the company says it had about $1.37 billion of U.S. federal NOLs at December 31, 2024.
The plan, effective August 14, 2025, aims to deter any investor or group from reaching 4.99% of the common stock. The release gives no current taxable income, net loss or cash figure.
The later date applies only if none of the company's 1.5% convertible notes due May 24, 2026 remain outstanding. Otherwise the loan comes due earlier.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $12.4 million | $16.7 million |
| Net income (loss) | -$20.2 million | -$13.6 million |
| Cash from operations | -$27.6 million | -$22.5 million |
| Cash and equivalents | $28.6 million | $25.8 million |
| Short-term investments | $18.0 million | $33.5 million |
Our latest story on this, dated Feb 20, 2025: "Heron Therapeutics extends Hercules loan maturity to as late as September 1, 2027". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 2, 2026: "Delaware court holds Heron CINVANTI patent claims invalid; Heron plans appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 2, 2026: "Delaware court holds Heron CINVANTI patent claims invalid; Heron plans appeal". The story links the filing or release it is based on. Read the story.
Heron Therapeutics, Inc. trades under the ticker HRTX on NASDAQ.
Heron Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:AXD2; LSE:0J4V.
The SEC Central Index Key (CIK) for Heron Therapeutics, Inc. is 818033. Its filings are on SEC EDGAR.
189,852,307 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Heron Therapeutics, Inc. under United States.
Our directory classifies Heron Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Heron Therapeutics, Inc. is US4277461020.
aibio.space lists Heron Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Heron Therapeutics, Inc. reported a net loss of $20.2 million for the fiscal year ended Dec 31, 2025, and used $27.6 million of cash in operations, per its annual report to the SEC.
$12.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$42.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.03,5.03,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,2.03,3.02,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio